Serum Th1 and Th2 cytokine balance in patients of superficial transitional cell carcinoma of bladder pre- and post-intravesical combination immunotherapy

Agarwal, Akhil; Agrawal, Usha; Verma, Saurabh; Mohanty, N.; Saxena, Sunita

doi:10.3109/08923970903300151

Cited by 38 publications

(37 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The systemic immune response is reported to be Th2 dominant in urinary bladder carcinoma patients, especially when recurrent. 1,2 The study of immune responses is especially important in urinary bladder cancer because of the frequent recurrences in spite of intravesical therapy given in these patients. 3 Local immune response in most tumours manifests as infiltration of CD4+/CD8+ T-cells, T-regulatory cells, dendritic cells, natural killer (NK) cells and macrophages.…”

Section: Introductionmentioning

confidence: 99%

Predictive role of serum and urinary cytokines in invasion and recurrence of bladder cancer

et al. 2017

Self Cite

View full text Add to dashboard Cite

Urothelial cancer patients are prone to recurrence, and there is no marker to predict which cases become refractory to the immunotherapy given to these patients. Tumour behaviour is decided by the dynamics between the pro-and antitumorigenic cytokines. In this study, 27 cytokines were estimated in serum and urine of 72 urothelial cancer patients and 42 healthy volunteer controls. Serum cytokines IL-1RA, IL-4 and RANTES were in significantly higher concentration in serum of patients compared to controls, while IL-2 was significantly less in concentration. Patients were found to have significantly high concentrations of 12 urinary cytokines

show abstract

Section: Introductionmentioning

confidence: 99%

Predictive role of serum and urinary cytokines in invasion and recurrence of bladder cancer

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…There is also a transient increase in IL-4 levels in the urine of BC patients within 24 h after instillation of BCG [19]. But on the other hand IL-4 level was significantly reduced in BC patients after instillation of combination immunotherapy [20]. Studies from our group reported no association of BC risk and BCG therapy with polymorphism in IL-4 intron3 [21].…”

Section: Pro-and Anti-inflammatory Cytokines Gene Variants and Their mentioning

confidence: 59%

Gene Variants in Predicting BCG Response to Urinary Bladder Cancer

Mittal

2012

Ind J Clin Biochem

View full text Add to dashboard Cite

“…Between Th1 and Th2 lymphocytes, phenomenon of mutual suppression activity is observed. It is known that for anti-tumor response, appropriate local induction of T1 helper cells (Th1) is necessary [26][27][28].…”

Section: Discussionmentioning

confidence: 99%

Effect of Different Bacillus Calmette-Guerin Substrains on Growth Inhibition of T24 Bladder Cancer Cells and Cytokines Secretion by BCG Activated Peripheral Blood Mononuclear Cells of PBMCs

Janaszek-Seydlitz¹,

Prygiel²,

Bucholc³

et al. 2014

Adv Clin Exp Med

View full text Add to dashboard Cite

Background. Bladder carcinoma is the most common malignancy of the urinary tract. Approximately 75-85% of patients present non-muscle invasive bladder cancer (NMIBC). Standard primary treatment for NIMBC is transurethral resection (TUR) followed by intravesical Bacillus Calmette-Guerin (BCG) immunotherapy. BCG has been accepted as the most effective agent in clinical use against NMIBC. Various BCG substrains are used worldwide for bladder cancer immunotherapy although the impact of used BCG substrain on BCG antitumor capacity is a little investigated. Objectives. The aim of this study was to compare the antitumor capacity and the ability to trigger cytokines production of three BCG substrains by stimulation of the local innate immunity in vitro. Material and Methods. The human bladder cancer cell line T24 was co-cultured with each of the BCG substrains: Moreau, Tice and RIVM alone or with BCG pretreated DCs (dendric cells) and allogenic PBMCs derived from the same donor. The inhibition of T24 cell growth was evaluated by 3 H-thymidine incorporation. Production of Th1 cytokines (IFN-γ, TNF-α, IL-12) and Th2 cytokines (IL-10, IL-4) was measured in cultures of BCG-activated PBMCs by ELISA test.Results. An approximately two-fold inhibition of T24 cell proliferation was observed as a direct cytotoxic effect of tested BCG substrains on T24 cells. However, BCG inhibited the growth of tumor cells mainly by activating the effector cells of innate immunity. About a 10-fold inhibition of T24 cell proliferation was observed when T24 cells were co-cultured with allogenic BCG pretreated DC s and PBMCs derived from the same donor. The PBMCs activated by compared live BCG substrains secreted large amounts of TNF-α and IFN-γ cytokines. Conclusions. Tested BCG substrains had little direct inhibitory effect on T24 cell proliferation. Moreau evolutionarily early BCG substrain showed similar strong, indirect antitumor effects as evolutionarily late BCG substrains Tice and RIVM (Adv Clin Exp Med 2014, 23, 6, 877-884).

show abstract

Serum Th1 and Th2 cytokine balance in patients of superficial transitional cell carcinoma of bladder pre- and post-intravesical combination immunotherapy

Cited by 38 publications

References 38 publications

Predictive role of serum and urinary cytokines in invasion and recurrence of bladder cancer

Predictive role of serum and urinary cytokines in invasion and recurrence of bladder cancer

Gene Variants in Predicting BCG Response to Urinary Bladder Cancer

Effect of Different Bacillus Calmette-Guerin Substrains on Growth Inhibition of T24 Bladder Cancer Cells and Cytokines Secretion by BCG Activated Peripheral Blood Mononuclear Cells of PBMCs

Contact Info

Product

Resources

About